D-1445-2020 Class III Terminated

Recalled by SUN PHARMACEUTICAL INDUSTRIES INC — Princeton, NJ

FDA drug recall D-1445-2020 was initiated by SUN PHARMACEUTICAL INDUSTRIES INC on Jul 6, 2020 and is designated Class III. Reason for recall: Cross contamination with other products - OOS discovered during routine stability testing for highest unknown impurity later identified as clozapine The recall status is terminated (terminated Jun 8, 2023). Affected quantity: 3516 bottles.

Recall details

Product Type
Drugs
Report Date
Aug 5, 2020
Initiation Date
Jul 6, 2020
Termination Date
Jun 8, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
3516 bottles

Product description

Clonazepam Orally Disintegrating Tablets, USP, 0.125 mg, 60-count bottle, Rx only, Mfg by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512, NDC 57664-783-86

Reason for recall

Cross contamination with other products - OOS discovered during routine stability testing for highest unknown impurity later identified as clozapine

Distribution pattern

Nationwide USA

Code information

Lot #: AA84106, Exp 9/2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1445-2020
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1445-2020. Report a data issue: hello@regdatalab.com.